Inclusion Criteria:

- Understand and sign a written IRB-approved informed consent form.

- Have a histologically confirmed solid tumor.

- Have progressive disease following standard/approved chemotherapy or have no
appropriate alternative therapy available.

- Have one or more tumors measurable or evaluable as outlined by modified RECIST or
evaluable by CT or MRI scan.

- Have an ECOG performance status of ≤ 2.

- Have a life expectancy of at least 3 months.

- Be ≥ 18 years old.

- Have a negative pregnancy test (if female of childbearing potential)

- Demonstrate acceptable hepatic function:

- Bilirubin ≤ upper limit of normal (ULN)

- AST (SGOT) and ALT (SGPT) ≤ 2.5 times ULN

- Demonstrate acceptable renal function:

- Serum creatinine ≤ 1.5 x ULN, OR calculated creatinine clearance ≥ 60 mL/min/1.73 m2
for patients with creatinine levels above institutional normal (Calculated according
to the Cockroft and Gault formula)

- Demonstrate acceptable hematologic status:

- Absolute neutrophil count ≥ 1500/mm3

- Platelet count ≥ 100,000/mm3 (measured within 72 hours prior to initial dose)

- Hemoglobin ≥ 9 g/dL

- Demonstrate acceptable coagulation status:

- PT or INR within 1.5x ULN

- PTT within 1.5x ULN

- Have recovered from prior treatments (eg, surgery, radiation, chemotherapy,
investigational therapies) sufficiently prior to Day 1 so that, in the opinion of the
Investigator and/or Medical Monitor, the protocol objectives would not be
compromised.

- Agree to use an effective contraceptive method (hormonal or barrier method; or
abstinence) for the duration of the study and for 30 days after the last dose (for
men and women of child-producing potential).

Exclusion Criteria:

- Have New York Heart Association Class III or IV cardiac disease, myocardial
infarction within the past 6 months prior to Day 1, unstable arrhythmia, or evidence
of ischemia on electrocardiogram (ECG).

- Have a seizure disorder requiring anticonvulsant therapy.

- Have active CNS metastasis. Patients with a history of CNS metastases will be
eligible if they have been treated and are stable without symptoms for 4 weeks after
completion of treatment, with image documentation required, and must be either off
steroids or on stable dose of steroids for ≥ 1 week prior to enrollment.

- Have severe, chronic obstructive pulmonary disease with hypoxemia.

- Have active, uncontrolled bacterial, viral, or fungal infections requiring systemic
therapy.

- Are pregnant or nursing.

- Have undergone radiation therapy, surgery, chemotherapy, or investigational therapy
within 28 days prior to study entry (6 weeks for nitrosoureas or Mitomycin C).

- Are unwilling or unable to comply with procedures required in this protocol.

- Have a known history of infection with HIV, hepatitis B, or hepatitis C.

- Have a serious nonmalignant disease that, in the opinion of the Investigator and/or
the Medical Monitor, could compromise protocol objectives.

- Are currently receiving any other investigational agent.

- Have exhibited allergic reactions to docetaxel, or a similar structural compound,
biological agent, or formulation.